

Initial Results from the CASCADE-FH Registry: CAscade SScreening for Awareness and Detection of Familial Hypercholesterolemia

Emily C. O'Brien¹, Emil M. deGoma², Patrick M. Moriarty³, MacRae F. Linton⁴, Michael D. Shapiro⁵, P. Barton Duell⁶, Christie M. Ballantyne⁶, William A. Neal⁷, Zahid S. Ahmad⁸, Danielle Duffy⁹, Lisa C. Hudgins¹⁰, Linda C. Hemphill¹¹, James A. Underberg¹², Karol E. Watson¹³, Samuel S. Gidding¹⁴, Seth J. Baum¹⁵, Katherine Wilemon⁷, Dave Pickhardt⁷, Iris Kindt⁷, Daniel J. Rader², Matthew T. Roe¹, Joshua W. Knowles¹⁶

¹Duke Clinical Research Institute, Durham, NC; ²University of Pennsylvania, Philadelphia, PA; ³University of Kansas, Kansas City, KS; ⁴Vanderbilt University, Nashville, TN; ⁵Oregon Health and Science University, Portland, OR; ⁶Baylor College of Medicine, Houston, TX; ⁷FH Foundation, South Pasadena, CA; ⁸UT Southwestern, Dallas, TX; ⁹Thomas Jefferson University, Philadelphia, PA; ¹⁰Rogosin Institute, New York, NY; ¹¹MGH Heart Center, Boston, MA; ¹²NYU Langone Medical Center, New York, NY; ¹³UCLA School of Medicine, Los Angeles, California; ¹⁴Nemours DuPont Hospital, Wilmington, DE; ¹⁵Preventive Cardiology, Boca Raton, FL; ¹⁶Stanford School of Medicine, Stanford, CA



Background


- Familial Hypercholesterolemia (FH) is a common genetic disease that leads to substantially elevated levels of low-density lipoprotein cholesterol (LDL-C)
- The 2013 ACC/AHA guidelines for treatment of Blood Cholesterol to Reduce ASCVD risk in adults denote an LDL-C level > 190 mg/dL (suggestive of FH) as an independent high-risk feature.
- Individuals with FH have a 20-fold increase in risk of early cardiovascular disease.
- Despite its prevalence, FH remains largely underrecognized: an estimated 1.5 million individuals in the U.S. have FH, yet fewer than 10% have been formally diagnosed.

The CASCADE FH Registry

- In 2013, the FH Foundation (a patient-led nonprofit organization) created the CASCADE-FH Registry.
- The CASCADE-FH Registry is a national initiative to increase FH awareness, characterize trends in treatment, and monitor clinical and patient-reported outcomes over time.
- CASCADE-FH represents a collaboration between The FH Foundation, cardiologists, primary care providers, lipid specialists, and patients with FH.

Methods

- CASCADE-FH uses a multi-pathway enrollment strategy to ensure maximum availability to interested FH patients
- Registry participants may enroll in CASCADE-FH by one of two methods:
 - 1) Enrollment by a provider in a specialized lipid clinic
 - 2) Self-enrollment via an interactive online portal for participants meeting pre-specified LDL criteria consistent with FH.



Data Elements

- Demographics
- Medical history and laboratory values
- Current lipid-lowering therapies
- Clinical events (hospitalizations, mortality)
- Patient-reported outcomes (QOL, treatment satisfaction)

Data Analysis

- Baseline characteristics presented as percentages for categorical variables and medians with interquartile ranges (IQRs) for continuous variables

Results

Table 1. Baseline Characteristics of the CASCADE-FH Patient Population (September 2013 – February 2015).

Variable	Overall (N=1605)	Online Portal (N=215; 13.4%)	Clinical Sites (N=1390; 86.6%)
Median age, years (IQR)	53.0 (37.0, 64.0)	52.0 (41.0, 60.0)	53.0 (36.0, 65.0)
<18 years of age	8.2	---	10.2
White race, %	81.4	92.7	79.6
Female sex, %	58.7	72.7	56.6
Formal FH diagnosis, %	97.4	80.6	100.0
Family member with FH, %	31.5	46.7	29.2
Prior MI, %	12.4	17.2	11.6
Prior PCI, %	17.0	19.4	16.6
Prior CABG, %	13.8	14.9	13.6
Diabetes	11.5	9.3	11.9
Hypertension	39.6	32.1	40.8
Current Smoker	6.2	3.7	6.6
Historical Highest LDL-C (mg/dL)	249.0 (211.0, 310.0)	290.0 (231.0, 355.0)	245.0 (210.0, 303.0)
Current LDL level (mg/dL)	143.0 (107.0, 196.0)	150.0 (118.0, 200.0)	143.0 (107.0, 196.0)

Abbreviations: MI=myocardial infarction; PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft
 *High-intensity statins defined as atorvastatin≥40 mg or rosuvastatin≥20 mg

Table 2. Treatment patterns of the CASCADE-FH Patient Population (September 2013 – February 2015).

Variable	Overall (N=1605)	Online Portal (N=215; 13.4%)	Clinical Sites (N=1390; 86.6%)
Currently treated with statins, %	74.1	73.0	76.0
Currently treated with high-intensity statins*, %	55.8	63.5	54.6
Number of LLT			
0	10.8	17.2	9.8
1	33.6	35.4	33.4
2	25.6	8.8	28.1
3+	30.0	38.6	28.7

*Among patients treated with statins
 Abbreviations: LLT=Lipid lowering therapy

Results (continued)

Figure 1. Percent of patients reporting that they "completely understand" the following about FH*






Figure 2. How satisfied are you that everything possible is being done to treat your FH?*



*Online portal patients only

Figure 3. How often do you worry that you may have a heart attack or die suddenly?*



Conclusions

- The CASCADE-FH Registry represents a collaboration between FH patients and clinical researchers who have partnered to address gaps in knowledge regarding FH screening, identification, and treatment.
- CASCADE-FH will evaluate future longitudinal treatment patterns and outcomes in this high risk patient population

Funding/disclosures

The CASCADE FH Registry has been supported by Amgen, Astra Zeneca, Regeneron, Sanofi and Aegerion.

Contact

Emily O'Brien, PhD
 Medical Instructor
 Duke Clinical Research Institute
 Duke Medical Center
 2400 Pratt Street
 Durham, NC 27705

Email: emily.obrien@duke.edu

